DiscoveryProbe™ FDA-approved Drug Library: Structured Evidence for High-Throughput Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 pre-dissolved, clinically approved bioactive compounds suitable for high-throughput and high-content screening (HTS/HCS) (ApexBio). This collection covers drugs approved by global regulatory agencies, including the FDA, EMA, HMA, CFDA, and PMDA, with thorough annotation of mechanisms such as receptor agonism/antagonism, enzyme inhibition, and ion channel modulation. The library has been employed to identify clinically viable carbapenem adjuvants against NDM-1-producing bacteria in benchmarked workflows (Qiu et al., 2024). Compounds are formatted in stable 10 mM DMSO solutions, supporting workflows with 12–24 month stability at -20°C to -80°C. This article extends previous interlinked resources by detailing evidence-based use cases, atomic claims, and defined boundaries for application in translational research.

Biological Rationale

Repurposing FDA-approved drugs accelerates drug discovery by leveraging established clinical safety and pharmacokinetic profiles (Qiu et al., 2024). High-throughput screening (HTS) of annotated compound libraries enables rapid identification of new indications or mechanisms for known drugs. The DiscoveryProbe™ FDA-approved Drug Library provides a curated, machine-ready resource for researchers targeting diverse biological pathways, including signaling, enzymatic, and receptor-mediated processes (Entinostat.net). This approach reduces the attrition rate associated with de novo drug discovery and facilitates drug repositioning, particularly in complex disease areas such as oncology and infectious disease (Biotin-hydrazide.com).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses drugs with well-characterized mechanisms, including:

• Receptor agonists and antagonists: e.g., beta-blockers, antihistamines, and opioid modulators.
• Enzyme inhibitors: e.g., statins (HMG-CoA reductase inhibitors), protease inhibitors, and kinase inhibitors.
• Ion channel modulators: e.g., calcium channel blockers and sodium channel inhibitors.
• Signal pathway regulators: e.g., mTOR, PI3K/AKT, and MAPK modulators.

Each compound is annotated with primary and secondary targets, regulatory status, and relevant pharmacological data, providing a foundation for mechanism-based screening. For example, recent studies used the DiscoveryProbe™ FDA-approved Drug Library to identify metal ion chelators as inhibitors of New Delhi metallo-lactamase-1 (NDM-1), demonstrating direct target engagement via biochemical and biophysical assays (Qiu et al., 2024).

Evidence & Benchmarks

• Contains 2,320 clinically approved bioactive compounds, each pre-dissolved at 10 mM in DMSO for immediate use in HTS/HCS workflows (ApexBio).
• Compounds are approved or listed by FDA, EMA, HMA, CFDA, PMDA, or recognized pharmacopeias, ensuring broad regulatory coverage (Entinostat.net).
• Demonstrated utility in screening for NDM-1 inhibitors: 12 compounds initially identified, with four (dexrazoxane, embelin, candesartan cilexetil, nordihydroguaiaretic acid) validated as effective metallo-β-lactamase inhibitors in vitro and in vivo (Qiu et al., 2024, DOI:10.1111/bph.16210).
• Standardized stability: 12 months at -20°C and 24 months at -80°C for all compounds, verified by analytical QC (ApexBio).
• Ready-to-screen formats: 96-well plates, deep well plates, and 2D barcoded screw-top tubes compatible with automated robotics (ApexBio).
• Validated for signal pathway, disease model, and pharmacological mechanism interrogation in oncology, neurodegeneration, and infectious disease settings (Entinostat.net).

This article builds on prior analyses by presenting structured, atomic evidence from recent high-impact studies, extending the guidance in Altretamine.com which focused on mechanistic insights for translational campaigns.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput screening (HTS) for drug repositioning and target identification.
• High-content screening (HCS) to interrogate cellular phenotypes and pathway modulation.
• Mechanistic studies using well-annotated, clinically established compounds.
• Combination therapy research and synergy testing with established standards (e.g., checkerboard MIC assays).

However, the library is not intended for:

• De novo chemical diversity expansion beyond approved drugs.
• Primary in vivo efficacy studies without prior validation in cell-based or biochemical assays.
• Screening highly unstable or volatile targets incompatible with DMSO or --20°C storage conditions.
• Use in clinical trials or patient diagnostics without additional regulatory clearance.

This article clarifies and extends the benchmarking framework provided by Cytochrome-C-Pigeon.com by outlining both validated and excluded use cases for translational researchers.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for every target class; mechanism annotation must guide screening design.
• Presence in the library does not imply regulatory approval for new indications; repositioning requires further validation.
• DMSO-solubilized compounds may not be compatible with all assay formats (e.g., aqueous-only systems).
• Compound stability is guaranteed only under recommended storage conditions; repeated freeze-thaw cycles may compromise integrity.
• Library does not substitute for orthogonal hit validation, structure-activity relationship (SAR) analysis, or in vivo pharmacology.

Workflow Integration & Parameters

The library is supplied in formats compatible with standard HTS and HCS platforms. Each compound is pre-dissolved at 10 mM in DMSO and aliquoted into 96-well or deep well plates, or 2D-barcoded tubes. Shipping is performed on blue ice (for evaluation samples) or at ambient/blue ice as specified. Stability is maintained for 12 months at -20°C and 24 months at -80°C, with quality control performed via LC/MS and HPLC. Integration into robotic screening workflows is facilitated by barcoded containers and machine-readable plate maps (ApexBio).

Recommended workflows include:

• Automated liquid handling for assay miniaturization (e.g., 384-well or 1536-well formats).
• Direct use in phenotypic, target-based, or biochemical assays after thawing and dilution.
• Data integration with cheminformatics tools for hit annotation and pathway mapping.
• Follow-up orthogonal validation with dose-response, SAR, and mechanistic assays.

For deeper integration strategies, see Gap-27.com, which offers a roadmap for accelerating therapy development using this and related libraries.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a reproducible, well-annotated foundation for high-throughput drug repositioning, target identification, and mechanistic research. Recent peer-reviewed evidence supports its use in identifying clinically actionable inhibitors of drug-resistant bacterial enzymes and in diverse disease models (Qiu et al., 2024). The platform's compatibility with automated screening, robust stability, and regulatory breadth make it a key resource for translational workflows. Researchers are encouraged to leverage this library for rapid hypothesis testing, pathway interrogation, and therapeutic innovation, while adhering to best practices for assay design and validation. For full specifications and ordering, see the DiscoveryProbe™ FDA-approved Drug Library product page.